Alan Lofquist

Dr. Lofquist has been serving as Vice President of Research and Development at Sedia since April 2021. Dr. Lofquist joined Sedia from Nortis Inc. in Woodinville, WA where he led R&D activities developing 3-D organ-on-chip models for animal and human toxicity screening. From 2011 to 2018 he was Director, then VP of R&D at Micronics in Redmond, WA, developing near-patient microfluidic-based in vitro molecular diagnostics from inception to FDA 510(k) submission and approval. Prior to Micronics, Dr. Lofquist spent several years in research management and senior scientist positions at Emergent Biosolutions/Trubion Pharmaceuticals in Seattle (now Aptevo) developing antibody-based biologics for the treatment of inflammatory diseases and cancer. Dr. Lofquist received his Ph.D. in Biological Sciences from the University of California, Irvine.